Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of NNC0519-0130 in Male Chinese Participants With Overweight or Obesity
NCT07004322Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- May 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing NNC0519-0130 with Placebo (2 arms). Primary endpoint: Area under the plasma concentration-time curve. Started May 2025; status: completed.
02
Drugs
NNC0519-0130
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07004322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07004322.